What is Astria Therapeutics Inc's earnings per share (EPS)?

Astria Therapeutics Inc (ATXS) reported diluted earnings per share of $-1.68 for fiscal year 2024. This represents a 30.6% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Astria Therapeutics Inc Financials

ATXS

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

This page shows Astria Therapeutics Inc (ATXS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

2/9

Astria Therapeutics Inc passes 2 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

0.86x

For every $1 of reported earnings, Astria Therapeutics Inc generates $0.86 in operating cash flow (-$81.2M OCF vs -$94.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

-$94.3M

YoY-29.3%

Astria Therapeutics Inc reported -$94.3M in net income in fiscal year 2024. This represents a decrease of 29.3% from the prior year.

EPS (Diluted)

$-1.68

YoY+30.6%

Astria Therapeutics Inc earned $-1.68 per diluted share (EPS) in fiscal year 2024. This represents an increase of 30.6% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$81.5M

YoY-19.1%

Astria Therapeutics Inc generated -$81.5M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 19.1% from the prior year.

Cash & Debt

$59.8M

YoY-65.9%

5Y CAGR+43.3%

10Y CAGR+15.1%

Astria Therapeutics Inc held $59.8M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

56M

YoY+37.5%

Astria Therapeutics Inc had 56M shares outstanding in fiscal year 2024. This represents an increase of 37.5% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-29.5%

YoY+0.5pp

5Y CAGR+44.1pp

Astria Therapeutics Inc's ROE was -29.5% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is up 0.5 percentage points from the prior year.

Capital Allocation

R&D Spending

$77.1M

YoY+83.0%

5Y CAGR+33.3%

10Y CAGR+17.3%

Astria Therapeutics Inc invested $77.1M in research and development in fiscal year 2024. This represents an increase of 83.0% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$325K

YoY+1200.0%

5Y CAGR+93.4%

10Y CAGR+3.6%

Astria Therapeutics Inc invested $325K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 1200.0% from the prior year.

ATXS Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	N/A	N/A	N/A	N/A	$0	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$77.1M+83.0%	$42.1M+22.9%	$34.3M+120.3%	$15.6M-39.2%	$25.6M+39.7%	$18.3M
SG&A Expenses	$34.5M+34.0%	$25.7M+33.6%	$19.2M+29.9%	$14.8M+25.0%	$11.8M+35.0%	$8.8M
Operating Income	-$111.6M-34.4%	-$83.0M-55.2%	-$53.5M+72.6%	-$195.0M-420.8%	-$37.4M-38.2%	-$27.1M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$94.3M-29.3%	-$72.9M-40.6%	-$51.8M+73.4%	-$194.9M-422.6%	-$37.3M-41.9%	-$26.3M
EPS (Diluted)	$-1.68+30.6%	$-2.42+31.8%	$-3.55+85.6%	$-24.58	$-12.20	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Revenue	$706K	N/A	N/A	N/A	$0	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$24.1M-6.9%	$25.9M-6.6%	$27.8M	N/A	$20.5M-1.0%	$20.7M+31.7%	$15.7M	N/A
SG&A Expenses	$10.7M+8.0%	$9.9M+7.2%	$9.2M	N/A	$8.5M+5.1%	$8.1M-3.9%	$8.4M	N/A
Operating Income	-$34.1M+4.8%	-$35.8M+3.2%	-$37.0M	N/A	-$29.0M-0.7%	-$28.8M-19.3%	-$24.1M	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$31.6M+4.3%	-$33.1M+1.9%	-$33.7M	N/A	-$24.5M-1.5%	-$24.2M-21.3%	-$19.9M	N/A
EPS (Diluted)	$-0.55+3.5%	$-0.57+1.7%	$-0.58	N/A	$-0.42+2.3%	$-0.43-13.2%	$-0.38	N/A

ATXS Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$342.4M+34.4%	$254.7M+10.4%	$230.6M+80.9%	$127.5M+168.7%	$47.5M+13.6%	$41.8M
Current Assets	$334.6M+33.4%	$250.9M+10.2%	$227.7M+79.2%	$127.1M+174.3%	$46.3M+18.9%	$39.0M
Cash & Equivalents	$59.8M-65.9%	$175.5M+755.2%	$20.5M-76.3%	$86.5M+247.0%	$24.9M+151.8%	$9.9M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$0	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$23.1M+100.0%	$11.6M+22.7%	$9.4M+81.0%	$5.2M-23.3%	$6.8M+12.0%	$6.1M
Current Liabilities	$19.1M+65.6%	$11.6M+27.5%	$9.1M+74.1%	$5.2M-18.6%	$6.4M+27.0%	$5.0M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$319.3M+31.3%	$243.1M+9.9%	$221.2M+80.9%	$122.3M+200.7%	$40.7M+13.9%	$35.7M
Retained Earnings	-$674.8M-16.2%	-$580.5M-14.4%	-$507.6M-11.4%	-$455.8M-74.7%	-$260.9M-16.7%	-$223.6M

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Total Assets	$271.9M-3.6%	$281.9M-9.2%	$310.4M-9.3%	$342.4M-5.3%	$361.6M-1.7%	$368.0M-2.9%	$378.8M+48.7%	$254.7M
Current Assets	$253.5M-5.6%	$268.6M-11.3%	$303.0M-9.5%	$334.6M-4.9%	$351.9M-1.7%	$357.9M-4.4%	$374.5M+49.2%	$250.9M
Cash & Equivalents	$96.3M+26.2%	$76.3M+40.3%	$54.4M-9.1%	$59.8M-26.1%	$80.9M-7.2%	$87.2M-49.3%	$172.0M-2.0%	$175.5M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$17.2M	N/A	N/A	$0	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$38.6M+80.3%	$21.4M+1.5%	$21.1M-8.7%	$23.1M+15.6%	$20.0M-4.4%	$20.9M+88.9%	$11.1M-4.1%	$11.6M
Current Liabilities	$23.5M+30.3%	$18.0M+3.5%	$17.4M-8.9%	$19.1M+21.7%	$15.7M-3.9%	$16.4M+47.8%	$11.1M-4.1%	$11.6M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$233.3M-10.5%	$260.5M-9.9%	$289.3M-9.4%	$319.3M-6.6%	$341.7M-1.6%	$347.1M-5.6%	$367.7M+51.3%	$243.1M
Retained Earnings	-$773.2M-4.3%	-$741.6M-4.7%	-$708.5M-5.0%	-$674.8M-3.9%	-$649.2M-3.9%	-$624.6M-4.0%	-$600.5M-3.4%	-$580.5M

ATXS Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$81.2M-18.7%	-$68.4M-57.2%	-$43.5M-44.4%	-$30.2M+7.2%	-$32.5M-22.3%	-$26.6M
Capital Expenditures	$325K+1200.0%	$25K-72.5%	$91K+333.3%	$21K-36.4%	$33K+175.0%	$12K
Free Cash Flow	-$81.5M-19.1%	-$68.5M-57.0%	-$43.6M-44.6%	-$30.2M+7.2%	-$32.5M-22.3%	-$26.6M
Investing Cash Flow	-$191.9M-242.1%	$135.1M+180.8%	-$167.1M-1231.2%	-$12.6M-299.3%	$6.3M+254.3%	-$4.1M
Financing Cash Flow	$157.2M+77.8%	$88.4M-38.9%	$144.7M+38.8%	$104.3M+155.2%	$40.9M+59.5%	$25.6M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Operating Cash Flow	-$32.3M+10.4%	-$36.1M-6.0%	-$34.0M-95.9%	-$17.4M+37.9%	-$28.0M-66.5%	-$16.8M+12.1%	-$19.1M+36.9%	-$30.2M
Capital Expenditures	$0	N/A	N/A	$0-100.0%	$20K	N/A	N/A	$16K
Free Cash Flow	-$32.3M	N/A	N/A	-$17.4M+38.0%	-$28.0M	N/A	N/A	-$30.3M
Investing Cash Flow	$52.3M-9.9%	$58.0M+102.9%	$28.6M+869.0%	-$3.7M-160.1%	$6.2M+109.1%	-$68.1M+46.0%	-$126.2M-6161.5%	-$2.0M
Financing Cash Flow	N/A	N/A	N/A	$0-100.0%	$15.3M+16177.7%	$94K-99.9%	$141.8M+61.2%	$88.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

ATXS Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-29.5%+0.5pp	-30.0%-6.6pp	-23.4%+135.9pp	-159.4%-67.6pp	-91.7%-18.1pp	-73.6%
Return on Assets	-27.5%+1.1pp	-28.6%-6.2pp	-22.5%+130.4pp	-152.9%-74.3pp	-78.6%-15.7pp	-62.9%
Current Ratio	17.49-4.2	21.73-3.4	25.13+0.7	24.42+17.2	7.25-0.5	7.74
Debt-to-Equity	0.07+0.0	0.050.0	0.040.0	0.04-0.1	0.170.0	0.17
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-4830.6%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	-4482.0%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-13.6%-0.9pp	-12.7%-1.0pp	-11.7%	N/A	-7.2%-0.2pp	-7.0%-1.5pp	-5.4%	N/A
Return on Assets	-11.6%+0.1pp	-11.7%-0.9pp	-10.9%	N/A	-6.8%-0.2pp	-6.6%-1.3pp	-5.3%	N/A
Current Ratio	10.78-4.1	14.89-2.5	17.39-0.1	17.49-4.9	22.38+0.5	21.87-12.0	33.83+12.1	21.73
Debt-to-Equity	0.17+0.1	0.080.0	0.070.0	0.07+0.0	0.060.0	0.06+0.0	0.03-0.0	0.05
FCF Margin	-4574.4%	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Prothena PRTA

$530.8M

Inhibrx Biosciences Inc INBX

$928.0M

Lexicon Pharmaceuticals Inc LXRX

$673.7M

Diamedica Therapeutics Inc DMAC

$349.2M

Replimune Group REPL

$694.4M

Frequently Asked Questions

Is Astria Therapeutics Inc profitable?

No, Astria Therapeutics Inc (ATXS) reported a net income of -$94.3M in fiscal year 2024.

What is Astria Therapeutics Inc's return on equity (ROE)?

Astria Therapeutics Inc (ATXS) has a return on equity of -29.5% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.

What is Astria Therapeutics Inc's free cash flow?

Astria Therapeutics Inc (ATXS) generated -$81.5M in free cash flow during fiscal year 2024. This represents a -19.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Astria Therapeutics Inc's operating cash flow?

Astria Therapeutics Inc (ATXS) generated -$81.2M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Astria Therapeutics Inc's total assets?

Astria Therapeutics Inc (ATXS) had $342.4M in total assets as of fiscal year 2024, including both current and long-term assets.

What are Astria Therapeutics Inc's capital expenditures?

Astria Therapeutics Inc (ATXS) invested $325K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does Astria Therapeutics Inc spend on research and development?

Astria Therapeutics Inc (ATXS) invested $77.1M in research and development during fiscal year 2024.

How many shares does Astria Therapeutics Inc have outstanding?

Astria Therapeutics Inc (ATXS) had 56M shares outstanding as of fiscal year 2024.

What is Astria Therapeutics Inc's current ratio?

Astria Therapeutics Inc (ATXS) had a current ratio of 17.49 as of fiscal year 2024, which is generally considered healthy.

What is Astria Therapeutics Inc's debt-to-equity ratio?

Astria Therapeutics Inc (ATXS) had a debt-to-equity ratio of 0.07 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Astria Therapeutics Inc's return on assets (ROA)?

Astria Therapeutics Inc (ATXS) had a return on assets of -27.5% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Astria Therapeutics Inc's cash runway?

Based on fiscal year 2024 data, Astria Therapeutics Inc (ATXS) had $59.8M in cash against an annual operating cash burn of $81.2M. This gives an estimated cash runway of approximately 9 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Astria Therapeutics Inc's Piotroski F-Score?

Astria Therapeutics Inc (ATXS) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Astria Therapeutics Inc's earnings high quality?

Astria Therapeutics Inc (ATXS) has an earnings quality ratio of 0.86x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.